Drug Trial Radar · NCT07862569
DOR/ISL in Pediatric Participants With HIV-1, <18 Years of Age and ≥ 35 kg
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
45
Planned (sponsor's estimate)
Start
Dec 23, 2026
Primary completion
Sep 24, 2029
Study completion Dec 23, 2033
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Oct 7, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 2 study of the pharmacokinetics, safety, and efficacy of oral doravirine/islatravir (100 mg/0.25 mg) \[MK-8591A\] in pediatric participants with human immunodeficiency virus type 1 (HIV-1) infection who are virologically suppressed or treatment-naive. The Base Study will last from Day 1 to Week 96. At Week 96, participants will be given the option to participate in an optional Study Extension and receive DOR/ISL until Week 240 or until it becomes commercially accessible, whichever is first.
Conditions
- HIV-1
- HIV Infection
Interventions
DOR/ISLDrug
DOR/ISL 100 mg/0.25 mg tablet taken by mouth qd
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the plasma conentration-time curve from dosing to 24 hours postdose (AUC0-24) of ISLTime frame: At designated timepoints on Day 28
- Maximum plasma concentration (Cmax) of ISLTime frame: At designated timepoints on Day 28
- Time to maximum plasma concentration (Tmax) of ISLTime frame: At designated timepoints on Day 28
- Apparent plasma terminal half-life (t½) of ISLTime frame: At designated timepoints on Day 28
- Apparent clearance (CL/F) of ISLTime frame: At designated timepoints on Day 28
- Volume of distribution (Vz/F) of ISLTime frame: At designated timepoints on Day 28
- Percentage of participants with ≥1 adverse event (AE) through Week 24Time frame: Up to ~24 weeks
- Percentage of participants discontinuing from study therapy due to AE(s) through Week 24Time frame: Up to ~24 weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
University of South Florida ( Site 1505)
Tampa, Florida
The Children's Hospital at Montefiore ( Site 1507)
The Bronx, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.